Legend Biotech (LEGN) reported $1.0B in revenue for fiscal 2025, +64.0% year on year. That ranks #1756 by revenue among 2853 SEC filers and #160 in Healthcare. It posted a net loss of −$297M for the same year. Revenue has grown 54.4% a year on average since 2018 ($49.1M then). The fiscal 2025 balance sheet shows $1.7B in total assets, $902M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractsWithCustomers | $1.0B | +64.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeProfitLossFromOperatingActivities | −$137M | +$173M | FY20252025-12-31 |
| Net incomeProfitLoss | −$297M | −$120M | FY20252025-12-31 |
| Operating cash flowCashFlowsFromUsedInOperatingActivities | −$100M | +$43.8M | FY20252025-12-31 |
| Capital expenditurePurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | $28.6M | +102.8% | FY20252025-12-31 |
| Total assetsAssets | $1.7B | +3.8% | FY20252025-12-31 |
| Shareholders' equityEquity | $1.0B | −3.7% | FY20252025-12-31 |
| CashCashAndCashEquivalents | $902M | +214.6% | FY20252025-12-31 |
| Long-term debtLongtermBorrowings | $0 | −100.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS, in US dollars.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 151 of 161 companies compared | −28.8% | |
| Operating marginRank 146 of 160 companies compared | −13.3% | |
| R&D as share of revenueRank 7 of 102 companies compared | 40.3% | |
| Cash as share of revenueRank 3 of 160 companies compared | 87.7% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Legend Biotech Corp
- Ticker
- LEGN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001801198
Filings
- 20-FMar 10, 2026Open filing →
- 20-FMar 11, 2025Open filing →
- 20-FMar 19, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Prestige Consumer HealthcarePBH | $1.1B | $190M |
| EmbectaEMBC | $1.1B | $95.4M |
| Acadia PharmaceuticalsACAD | $1.1B | $391M |
| Legend BiotechLEGN | $1.0B | −$297M |
| Tandem Diabetes CareTNDM | $1.0B | −$205M |
| Guardant HealthGH | $982M | −$416M |
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Legend Biotech — Key figures |url=https://companiesranked.com/en/company/legend-biotech |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Legend Biotech — Key figures. CompaniesRanked. https://companiesranked.com/en/company/legend-biotechBibTeX
@misc{companiesranked-en-company-legend-biotech-2026,
author = {{CompaniesRanked}},
title = {{Legend Biotech — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/legend-biotech}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001801198-26-000008 · March 10, 2026
{{cite web |title=Legend Biotech — Key figures — 20-F (0001801198-26-000008) |url=https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-10}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.